IgGenix

We’re excited to share a Healio feature on research uncovering 60+ mAbs linked to alpha-gal syndrome-a step closer to new allergy treatments! At IgGenix, we’re committed to developing next-gen antibody therapeutics for severe allergies. Read more: bit.ly/3FCTLzR

This #NationalPeanutMonth, we're highlighting the #ACCELERATEPeanut Study using IGNX001 for peanut allergies. #IgGenix is on a mission to empower people to live life without the constant fear of a life-threatening allergic reaction. bit.ly/4kGqjc8

On #InternationalWomensDay, we celebrate the amazing achievements of #womenInSTEM and #womanleaders like #IgGenix CEO Jessica Grossman, MD, overseeing significant strides in #allergyresearch. Let's applaud #womeninstem empowering future generations!

#TeamIgGenix's dedication and passion for innovative solutions addressing allergic diseases are truly inspiring! Every step forward is progress towards the aim of benefiting countless individuals affected by severe to life-threatening allergies. #EmployeeAppreciationDay

We're excited to present new data on #AlphagalSyndrome and connect with the biotech community at #AAAAI2025 / #WAO2025! Join us we share our latest advancements in the fight against #allergicdiseases.

There's no cure for #PeanutAllergies—but #TeamIgGenix is fighting to change that. Discover #ACCELERATEPeanut, a new study that could singlehandedly revolutionize treatment not only for peanut allergy but other food allergies, too. Learn more: bit.ly/4dxWIhb

#IgGenix will present new data on #AlphagalSyndrome (AGS) at #AAAAI2025 / WAO Joint Congress! These data enrich our understanding of AGS and may help lead to breakthrough therapies for people suffering from this complex condition. More info: bit.ly/4gvwufH

Exciting news! #TeamIgGenix will be attending the #AAAAI2025 Annual Meeting / WAO Joint Congress! Come join us as we showcase exciting new data for the treatment of alpha-gal syndrome, and share the latest updates in our mission to solve #allergies. #AllergyResearch

Struggling with a #PeanutAllergy? #ACCELERATEPeanut, a new study led by #TeamIgGenix, raises hope for those affected by peanut allergies— and possibly other food allergies as well—with a breakthrough solution. Check out this article for more info: bit.ly/40BgK57

The #ACCELERATEPeanut study is exploring a novel mechanism of action to improve safety and expand options for patients. Here, Dr. Tong shares why this groundbreaking Phase 1 trial is an exciting step forward. Visit @NACEresearch Allergy Studies Directory: bit.ly/4dxWIhb

#Winterallergies are often triggered by what’s inside—dust mites, pet dander, mold—rather than the cold outdoors. Learn more about the causes, symptoms, and how to manage them in this article from @AllergyAsthmaHQ: bit.ly/3BDnUgK

Accidental allergen exposure can be life-threatening. The #ACCELERATEPeanut study explores new ways to protect patients—without using direct allergen exposure. Visit the @NACEresearch Allergy Studies Directory to learn more: bit.ly/4dxWIhb

How does IGNX001 neutralize peanut allergens? In a Q&A with @GoHealio, CEO Dr. Jessica Grossman shares insights on the science behind our ACCELERATE Peanut study & its potential to transform #peanutallergy care. Read: bit.ly/4ijJibo #ACCELERATEPeanut @HealioAllergy

We’re thankful for the hard work that #TeamIgGenix and @NACEresearch partners have achieved this year. From launching the #ACCELERATEPeanut study to advancing allergy research, we couldn’t do it without you. Wishing everyone a happy and safe Thanksgiving!

Our #ACCELERATEPeanut study transforms harmful IgE antibodies into protective IgG4 antibodies, working to prevent severe allergic reactions before they happen. Watch Dr. Andrew Carr of St. Vincent's Hospital explain the importance of this therapy for all age groups.

Being part of Lilly Gateway Labs means working with biotech leaders to advance innovation in #allergy research. Together, we’re driving progress toward better therapies for allergic diseases.

An estimated 16.5 million U.S. adults have #atopicdermatitis, with 40% experiencing moderate to severe disease, according to @nationaleczema. At IgGenix, we’re committed to finding new solutions for #eczema - during #HealthySkinMonth and beyond.

Fall means #seasonalallergies for a quarter of U.S. adults. At IgGenix, we’re working to tackle environmental allergens through groundbreaking research, so people can enjoy the season without the sneezing! Learn more about our work: iggenix.com

Last month, IgGenix participated in #ASCIA2024, where we showcased our ongoing work on the #ACCELERATEPeanut study. We’re proud to be part of important conversations shaping the next generation of treatments for #allergies and IgE-mediated diseases.

30 - 40% of the world’s population suffers from one or more allergic conditions, according to @StanfordMed. Understanding these reactions is key to developing solutions that could improve millions of lives. Explore our work: iggenix.com #WorldAllergyAwarenessDay